DAX22.380 -2,0%Est505.501 -2,0%MSCI World4.343 -0,1%Top 10 Crypto9,1200 -2,8%Nas21.648 -2,0%Bitcoin60.408 +0,1%Euro1,1567 -0,1%Öl112,2 +4,3%Gold4.503 -3,1%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Vincorion VNC001 Rheinmetall 703000 Vonovia A1ML7J SAP 716460 Siemens Energy ENER6Y Lufthansa 823212 NVIDIA 918422 Infineon 623100 Volkswagen (VW) vz. 766403 Allianz 840400 DroneShield A2DMAA Deutsche Telekom 555750 Mercedes-Benz Group (ex Daimler) 710000 Deutsche Bank 514000 Siemens 723610
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX geht tiefrot ins Wochenende -- US-Börsen zum Wochenschluss auf Talfahrt -- Schwere Vorwürfe gegen Super Micro -- TUI, Novo Nordisk, Xpeng, Rüstungsaktien, Alibaba, Vincorion, Bayer im Fokus
Top News
Gold-Rally 2026: Analyst prognostiziert 6.000 US-Dollar bis Jahresende Gold-Rally 2026: Analyst prognostiziert 6.000 US-Dollar bis Jahresende
Top-News der Woche: Diese Themen am Aktienmarkt waren in dieser Woche wichtig für Börsenanleger Top-News der Woche: Diese Themen am Aktienmarkt waren in dieser Woche wichtig für Börsenanleger
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

PTC Therapeutics Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
56,00 EUR -1,50 EUR -2,61 %
STU
65,25 USD -0,07 USD -0,11 %
nachbörslich
BTT
finanzen.net zero
PTC Therapeutics jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.4,80 Mrd. EUR

KGV9,76Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1W0MW

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS69366J2006

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolPTCT

PTC Therapeutics Aktien News

DatumMeistgelesen
PR NewswirePTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference
PR NewswirePTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswirePTC Therapeutics Announces Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) in Japan
Wer­bungPTC Therapeutics-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswirePTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswirePTC Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
PR NewswirePTC Therapeutics Announces Health Canada Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
PR NewswirePTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireSandisk Set to Join S&P 500; Upwork, First Interstate BancSystem, PTC Therapeutics to Join S&P SmallCap 600
PR NewswirePTC Therapeutics to Host R&D Day
PR NewswirePTC Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
PR NewswirePTC Therapeutics to Participate at Upcoming Investor Conferences
PR NewswirePTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswirePTC Therapeutics to Host Conference Call to Discuss Third Quarter 2025 Financial Results
PR NewswirePTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswirePTC Therapeutics to Participate at Upcoming Investor Conferences
PR NewswirePTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA
PR NewswirePTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
PR NewswirePTC Therapeutics Announces FDA Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
PR NewswirePTC Therapeutics to Host Conference Call to Discuss Second Quarter 2025 Financial Results
PR NewswireSephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
PR NewswirePTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
PR NewswirePTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
PR NewswirePTC518 PIVOT-HD Study Achieves Primary Endpoint
PR NewswirePTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswirePTC Therapeutics to Participate at Upcoming Investor Conferences
PR NewswirePTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results
PR NewswirePTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswirePTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe
PR NewswirePTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies
PR NewswirePTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
PR NewswirePTC Therapeutics to Participate in Upcoming Investor Conferences
PR NewswirePTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia

PTC Therapeutics News

PTC Therapeutics News: auf dieser Seite finden Sie alle PTC Therapeutics News und Nachrichten zur PTC Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch PTC Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um PTC Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.